Stockreport

Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline [Seeking Alpha]

Halozyme Therapeutics, Inc.  (HALO) 
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: halozyme.com/investors/default.aspx
PDF Helen Torley, President and CEO, highlighted that "2025 was one of the most significant and value-creating years in Halozyme's history," citing the expansion of the por [Read more]